One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Table of Contents
doi : 10.1016/S0923-7534(22)03798-X
Volume 33, Issue 9, September 2022, Pages i-ii
The deleterious effect of acetaminophen in cancer immunotherapy
P.Berraondo123R.J.Sullivan45
Bridging the implementation gap: delivering complex genomic analysis for routine cancer care
P.A.Beer1A.V.Biankin234
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A.Oaknin1T.J.Bosse2C.L.Creutzberg3G.Giornelli4P.Harter5F.Joly67D.Lorusso89C.Marth10V.Makker1112M.R.Mirza13J.A.Ledermann1415N.Colombo1617ESMO Guidelines Committee
The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline
M.Di Maio1E.Basch2F.Denis34L.J.Fallowfield5P.A.Ganz6D.Howell7C.Kowalski8F.Perrone9A.M.Stover210P.Sundaresan1112L.Warrington13L.Zhang14K.Apostolidis15J.Freeman-Daily16C.I.Ripamonti17D.Santini18ESMO Guidelines Committee
Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches
F.Cortiula12B.Reymen1S.Peters3P.Van Mol4E.Wauters4J.Vansteenkiste4D.De Ruysscher1L.E.L.Hendriks5
Impact of acetaminophen on the efficacy of immunotherapy in cancer patients
A.Bessede1†A.Marabelle2†J.P.Guégan1F.X.Danlos2S.Cousin3F.Peyraud12N.Chaput456M.Spalato3G.Roubaud3M.Cabart3M.Khettab7A.Chaibi1C.Rey1I.Nafia1F.X.Mahon37J.C.Soria8A.Italiano237
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas
G.Ghilardi123†E.A.Chong123†J.Svoboda123P.Wohlfarth4S.D.Nasta13S.Williamson5J.D.Landsburg13J.N.Gerson13S.K.Barta123R.Pajarillo123J.Myers5A.I.Chen5L.Schachter5R.Yelton12H.J.Ballard13A.Hodges Dwinal5S.Gier23D.Victoriano23…S.J.Schuster123â€
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
M.Maio1P.A.Ascierto2L.Manzyuk3D.Motola-Kuba4N.Penel5P.A.Cassier6G.M.Bariani7A.De Jesus Acosta8T.Doi9F.Longo10W.H.MillerJr1112D.-Y.Oh131415M.Gottfried16L.Xu17F.Jin17K.Norwood17A.Marabelle18
Whole-genome and transcriptome analysis enhances precision cancer treatment options
E.Pleasance1†A.Bohm12†L.M.Williamson1J.M.T.Nelson1Y.Shen1M.Bonakdar1E.Titmuss1V.Csizmok1K.Wee1S.Hosseinzadeh12C.J.Grisdale1C.Reisle1G.A.Taylor1E.Lewis1M.R.Jones1D.Bleile1S.Sadeghi1W.Zhang1…J.Laskin3
Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy – an ancillary study of the SAKK 09/10 randomized clinical trial
A.Dal Pra12P.Ghadjar34S.Hayoz5V.Y.T.Liu6D.E.Spratt7D.J.S.Thompson8E.Davicioni6H.-C.Huang6X.Zhao6Y.Liu6C.Schär5P.Gut9L.Plasswilm210T.Hölscher11B.Polat12G.Hildebrandt13A.-C.Müller14A.Pollack1…D.M.Aebersold2
Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial
Y.Kurokawa1Y.Honma2A.Sawaki3Y.Naito4S.Iwagami5Y.Komatsu6T.Takahashi1T.Nishida78T.Doi9
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study
F.Dimitriou123K.Namikawa4I.L.M.Reijers5E.I.Buchbinder6J.A.Soon7A.Zaremba8P.Teterycz9M.J.Mooradian10E.Armstrong11Y.Nakamura12M.G.Vitale13L.E.Tran14X.Bai15C.Allayous16S.Provent-Roy17A.Indini18P.Bhave19M.Farid20…G.V.Long1331
Fewer cetuximab-related skin-toxicities in colorectal cancer patients treated with encorafenib: a Yin and Yang effect of ERK paradoxical activation
J.Ciccolini1G.Milano2
In the phase III IMmotion151 trial of metastatic renal cell carcinoma the easy-to-implement modified Glasgow prognostic score predicts outcome more accurately than the IMDC score
J.Saal123T.Bald23M.Hölzel23M.Ritter34P.Brossart13J.Ellinger34†N.Klümper234â€
Does the result of a small-scale phase II study of nivolumab for cancer of unknown primary justify regulatory approval?
Y.Sasaki12C.Sakaguchi1E.Satoh12
VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up
S.Loibl1J.Jassem2A.Sonnenblick3D.Parlier4E.Winer5J.Bergh6R.D.Gelber7E.Restuccia8Y-H.Im9C.Huang10F.Dalenc11I.Calvo12M.Procter13C.Caballero14E.Clark15H.L.Gomez Moreno16J.Bliss17G.Viale18…M.Piccart20
Corrigendum to “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’�: [Ann Oncol Volume 33, Issue 1, January 2022, Page 117]
M.A.Dimopoulos1P.Moreau2E.Terpos1M.V.Mateos3S.Zweegman4G.Cook5M.Delforge6R.Hájek7F.Schjesvold89M.Cavo1011H.Goldschmidt12T.Facon13H.Einsele14M.Boccadoro15J.San-Miguel16P.Sonneveld17U.Mey18EHA Guidelines Committee ESMO Guidelines Committee
